Sedana Medical AB ( (SE:SEDANA) ) just unveiled an update.
Sedana Medical AB reported a record quarter with net sales increasing by 18% compared to the same period in 2024, driven by its focus on inhaled sedation products. Despite facing negative currency effects, the company showed improved financial performance with a reduced EBITDA loss and positive cash flow from operating activities, highlighting its strong market positioning and operational resilience.
More about Sedana Medical AB
Sedana Medical AB is a medtech and pharmaceutical company specializing in inhaled sedation for mechanically ventilated patients in intensive care. The company combines the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane) to enhance patient care during and after sedation. Founded in 2005, Sedana Medical is listed on Nasdaq Stockholm and is headquartered in Stockholm, Sweden.
Average Trading Volume: 702,265
Current Market Cap: SEK1.02B
See more data about SEDANA stock on TipRanks’ Stock Analysis page.